Skip to main content

Table 1 Characteristics of ICC patient (N = 28), treatment (N = 23) and lesion (N = 34) population at baseline

From: Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma

Characteristic N (%) unless indicated otherwise
Age in years, median (range) 67 (42–81)
Sex
Male 8 (44%)
Female 10 (56%)
BMI, median (range) 27 (21–35)
Hepatic tumour burden (%)a, median (range) 18 (1–42)
Extrahepatic metastasesb 10 (56%)
Prior therapies
Chemotherapyb 13 (72%)
Hepatic resection 2 (11%)
TACEc to liver 3 (17%)
Radiotherapy 2 (11%)
Cirrhosis present 1 (6%)
Treatment to whole liver 12 (67%)
Prescribed amount of 90Y for treatment in GBq, median (range) 1.5 (0.6–3.0)
Time to follow-up FDG PET/CT in days, median (range) 51 (42–79)
Lesion volume (cc), median (range) 143 (11–1272)
Lesion SUVmax, median (range) 11.5 (5.0–26.4)
Lesion TLG, median (range) 598 (54–8007)
Overall survival in months, median (range)d 6.5 (4.4–19.9)
  1. aAs measured from FDG PET
  2. bIncluding cisplatin, carboplatin and gemcitabine
  3. cTransarterial chemoemnolisation
  4. dN = 20 (8 patients had no deceased records)